PT  - JOURNAL ARTICLE
AU  - Vargas, Matheus J. T.
AU  - Chandrasekhar, Mithileshwari
AU  - Kwon, Yong Je
AU  - Deijs, Gerrit Sjoerd
AU  - Corazza, Carsten Ma On Wong
AU  - Chai, Angela (Wai Yin)
AU  - Binedell, Rebecca L.
AU  - Jose, Ellen
AU  - Govind, Bhavesh
AU  - Huyet, Laura
AU  - Patel, Pooja K.
AU  - Reshef, Gabrielle
AU  - Kumar, Vijaya
AU  - Lowe, Tiffany
AU  - Powell, Robert J.
AU  - Jina, Kieran C.
AU  - Walker, Flynn C.W.
AU  - Talemaitoga, Apisalome
AU  - Simpson, M. Cather
AU  - Williams, David E.
TI  - Individual vaccine efficacy variation with time since mRNA BNT162b2 vaccination estimated by rapid, quantitative antibody measurements from a finger-prick sample
AID  - 10.1101/2021.11.30.21267102
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.30.21267102
4099  - http://medrxiv.org/content/early/2021/12/23/2021.11.30.21267102.short
4100  - http://medrxiv.org/content/early/2021/12/23/2021.11.30.21267102.full
AB  - We show that an individual’s immune status to Covid-19 can be monitored through quantitative antibody measurements using a method based on centrifugal microfluidics, specifically designed for speed to result (20 min), high throughput (8 samples simultaneously) and accuracy from a finger-prick blood sample. Anti-Receptor Binding Domain (RBD) IgG concentration showed a log-normal distribution with mean decreasing with time following the second vaccination with mRNA BNT162b2 (Pfizer). Using a model for an individual’s antibody concentration-dependent vaccine efficacy allowed comparison with literature data on changing vaccine efficacy against symptomatic disease across a population. Even though the trial was small (n = 100) the computed population vaccine efficacy was in reasonable agreement with that obtained from a large population survey. The derived parameters for the vaccine efficacy model were in good agreement with those expected from previous studies and from a simple theoretical model. The results and modelling show that the major proportion of breakthrough infections are for people whose antibody concentration is in the tail of the distribution. The results provide strong support for personalized booster programmes that, by targeting people in the tail of the distribution, should be more effective at diminishing breakthrough infection and optimising booster dose supply than a program that simply mandates a booster at a specific post-vaccination time point.Competing Interest StatementMCS and KCJ are Directors of Orbis Diagnostic Ltd. Other than AT, authors are shareholders and/or employees of Orbis Diagnostics Ltd or its lead investor, Pacific Channel.Clinical TrialACTRN12621000907842 U1111-1267-3749Clinical Protocols https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382309&isReview=true Funding StatementThis study was funded by Orbis Diagnostics LtdAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Trail registered on Australia New Zealand Clinical Trials Registry. Registration number ACTRN12621000907842; Universal Trial Number U1111-1267-3749 Ethics approval to Orbis Diagnostics Ltd by Health and Disability Ethics Committees, 133 Molesworth Street, Thorndon, Wellington, 6011, New Zealand Approval number 21/NTB/212I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript or supplementary appendices